Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies
Warnatz, Klaus ; Jolles, Stephen ; Agostini, Carlo ; Vianello, Fabrizio ; Borte, Michael ; Bethune, Claire ; Grigoriadou, Sofia ; Richter, Alex ; Jain, Rashmi ; Lowe, David M ... show 3 more
Warnatz, Klaus
Jolles, Stephen
Agostini, Carlo
Vianello, Fabrizio
Borte, Michael
Bethune, Claire
Grigoriadou, Sofia
Richter, Alex
Jain, Rashmi
Lowe, David M
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-02-01
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Many patients with immunodeficiencies require lifelong immunoglobulin replacement therapy (IgRT). In a multicenter, randomized, open-label, crossover, non-inferiority 3-month-trial, we compared the impact of the subcutaneous immunoglobulin Gammanorm® administered via pump or syringe (rapid push). Primary endpoint was the life quality index (LQI), secondary endpoints were QoL (SF36v2), satisfaction (TSQM-11), disease and treatment burden (PRISM), incidence of infections and adverse events (AE), treatment costs, and IgG levels. 28/30 patients completed the study. Most of the endpoints were comparable. Drug administrations with rapid push were more frequent, but reduced total time expenditure and some costs. Of the TSQM-11/LQI/SF36 components only "treatment interference with daily activities" was superior with pump and two QoL domains with rapid push. Both delivery devices showed favorable safety. Rapid push was preferred by 34.5% of patients. It proved to be an efficacious and cost-effective alternative to pumps adding to patient choice and increasing flexibility during long-term IgRT.
Citation
Warnatz K, Jolles S, Agostini C, Vianello F, Borte M, Bethune C, Grigoriadou S, Richter A, Jain R, Lowe DM, Katelaris C, Milito C, Cook MC. Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies. Clin Immunol. 2022 Mar;236:108938. doi: 10.1016/j.clim.2022.108938
Type
Article